Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD) (ADVANCE)

This study has been completed.
Information provided by:
Novartis Identifier:
First received: August 29, 2005
Last updated: November 12, 2008
Last verified: November 2008

This study evaluates the tolerability and safety of 3 months treatment with PTK787 tablets given daily. It also explores the efficacy of the compound in patients with wet age-related macular edema.

In Cohort 1 verteporfin/PDT is the active control. The protocol was amended to reflect the current standard of care for AMD. As a result, ranibizumab is the active control for Cohort 2.

Condition Intervention Phase
Wet Age-Related Macular Degeneration
Drug: PTK787
Drug: Placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Masked, Multicenter, Phase I/II Study of the Safety of PTK787 Administered to Patients With Predominantly Classic , Minimally Classic or Occult With no Classic Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Safety as assessed by visual acuity measurements, ophthalmic examinations, vital signs, laboratory assessments, and adverse events up to 12 months [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Change in macular edema from Baseline up to Month 3 Change in best-corrected visual acuity (BCVA) from Baseline up to Month 3 Change in size of fluorescein leakage Baseline up to Month 3 [ Time Frame: from baseline up to 3 months ] [ Designated as safety issue: Yes ]

Enrollment: 50
Study Start Date: September 2005
Primary Completion Date: November 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: PTK787
Visudyne® + PTK787, 500 mg/day
Experimental: 2 Drug: PTK787
Visudyne® + PTK787 1000 mg/day
Placebo Comparator: 3 Drug: Placebo
Visudyne® + Placebo


Ages Eligible for Study:   65 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria

  • Male ≥ 65 years old or female ≥ 50 years old, with aged related macular degeneration
  • Patients with subfoveal choroidal neovascularization secondary to AMD

Exclusion criteria

  • Eye disease that may result in visual loss during the study
  • Uncontrolled high blood pressure, despite chronic stable treatment: systolic ≥ 140 mmHg, Diastolic ≥ 90 mmHg
  • Chronic therapy with topical, local or systemic corticosteroids.
  • Use of other investigational drugs within 30 days
  • Pregnant or nursing (lactating) women.

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00138632

United States, California
Retina-Vitreous Associates Medical Group
Beverly Hills, California, United States, 90211
United States, Colorado
Porter Adventist Hospital, Eye Lab
Denver, Colorado, United States, 80210
United States, Florida
USF Eye Institute
Tampa, Florida, United States, 33612-4742
United States, Illinois
Springfield Clinic, LLP
Springfield, Illinois, United States, 62701
United States, Maryland
Wilmer Eye Institute
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Lahey Clinic Medical Center, Eye institute
Peabody, Massachusetts, United States, 01960
United States, South Dakota
Black Hills Regional Eye Institute
Rapid City, South Dakota, United States, 05770
Australia, New South Wales
Novartis Investigative Site
Parramatta, New South Wales, Australia, 2150
Novartis Investigational Site
Sydney, New South Wales, Australia, 2000
Novartis Investigative Site
Westmead, New South Wales, Australia, 2145
Australia, Victoria
Novartis Investigative Site
East Melbourne, Victoria, Australia, 3002
Sponsors and Collaborators
Study Chair: Novartis Customer Information Novartis
  More Information

Responsible Party: External Affairs, Novartis Pharmaceuticals Identifier: NCT00138632     History of Changes
Other Study ID Numbers: CPTK787E2201 
Study First Received: August 29, 2005
Last Updated: November 12, 2008
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration

Keywords provided by Novartis:
Wet Age-related macular degeneration

Additional relevant MeSH terms:
Choroidal Neovascularization
Macular Degeneration
Neovascularization, Pathologic
Choroid Diseases
Eye Diseases
Pathologic Processes
Retinal Degeneration
Retinal Diseases
Uveal Diseases
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors processed this record on May 22, 2016